ndia's largest private fuel retailer, Nayara Energy, has announced a reduction in retail fuel prices, cutting petrol by ₹5 per litre and diesel by ₹3 per litre across its nationwide network of more than 7,000 fuel stations. The revised prices came into effect on July 1, offering immediate savings to millions of customers who refuel at Nayara outlets. The move marks the first major retail fuel price cut by any oil marketing company in more than two years. 

The price reduction follows a decline in international crude oil prices after geopolitical tensions in West Asia eased. With concerns over supply disruptions gradually fading and oil shipments through key global trade routes returning to normal, crude prices have softened in recent weeks. Nayara's decision reflects these changing market conditions and passes some of the benefit directly to consumers. 

Unlike Nayara, state-owned fuel retailers have not yet revised their petrol and diesel prices. As a result, the private retailer has become the first company in the country to lower retail fuel prices in response to the recent fall in global oil prices. Industry experts believe the move could increase competition in the fuel retail market and may encourage other companies to review their pricing strategies if crude prices remain stable. 

The price cut is expected to provide meaningful relief for daily commuters, commercial drivers, logistics operators and businesses that depend heavily on transportation. Even a modest reduction in fuel costs can help lower operating expenses over time, especially for fleet owners and small businesses managing rising input costs.

For consumers, the savings can add up quickly. A motorist filling a 40-litre petrol tank at a Nayara outlet will save ₹200 in a single refill, while diesel vehicle owners filling the same quantity will save ₹120. Although these may appear to be modest amounts individually, regular refuelling throughout the month could result in noticeable savings for households and businesses alike.

The development also comes at a time when inflation and transportation costs remain key concerns for consumers. Lower fuel prices have the potential to reduce operating costs across several sectors, including logistics, agriculture and public transport. While any broader impact on prices of goods and services may take time, reduced fuel expenses are generally viewed as a positive sign for the economy.

Market analysts will now closely watch global crude oil trends over the coming weeks. If international oil prices continue to remain under pressure, there could be further adjustments in domestic fuel pricing by both private and public sector retailers. However, future revisions will continue to depend on global crude movements, currency fluctuations and overall market conditions.

Nayara Energy's latest decision highlights how international energy markets directly influence fuel prices in India. For customers using the company's extensive retail network, the reduction provides welcome relief at the pump while signalling a potentially more competitive pricing environment in the country's fuel retail sector.

Disclaimer: This image is taken from The Hindu.  

India has long been known as the “Pharmacy of the World,” a title earned through its immense contribution to global healthcare. The country produces nearly 20% of the generic medicines used worldwide, exports vaccines to more than 150 nations, and ranks among the largest pharmaceutical manufacturing centers on the planet. A crucial question deserves greater discussion: how many original pharmaceutical innovations has India introduced in recent years? Since 2021, the number stands at just eight.

These breakthroughs have come from a small group of domestic companies, including Zydus Lifesciences, Wockhardt, Orchid Pharma, Biocon, ImmunoACT, and ENTOD Pharmaceuticals. Their achievements span areas such as new drug molecules, biologics, cell-based therapies, immunotherapies, and advanced formulations, demonstrating that Indian researchers and companies are fully capable of producing world-class innovations.

Yet when compared with global innovation leaders, the gap becomes apparent. Over the same period, the United States generated roughly 500 significant pharmaceutical innovations, including around 160 new chemical entities (NCEs). China recorded nearly 150 innovations, with close to 95 homegrown NCEs. India, despite its scientific expertise and strong manufacturing foundation, remains far behind.

The issue is not a lack of talent or scientific capability. Instead, the challenge lies within the broader innovation ecosystem. Creating a new medicine requires years of research, extensive clinical testing, regulatory approvals, and substantial financial investment, often with no certainty of success. One policy issue that receives limited attention in India is clinical data exclusivity. In leading pharmaceutical markets such as the United States, European Union, and China, innovators receive a period during which competitors cannot rely on the original developer’s clinical trial data to secure regulatory approval for similar products. This protection differs from patents and recognizes the enormous time and resources invested in generating clinical evidence, often consuming a significant portion of a product’s patent life.

India currently lacks a comparable system for most locally developed pharmaceutical innovations. Supporters of data exclusivity argue that a well-balanced framework would not significantly affect long-term medicine affordability or access. Competition would still enter the market after a defined period, as it does elsewhere. However, such protection could encourage greater investment in drug discovery, address unmet medical needs, close therapeutic gaps, improve patient outcomes, and strengthen India’s position in high-value pharmaceutical innovation.

It is therefore unsurprising that many Indian companies actively engaged in research and development support the introduction of such measures. Their argument is simple: without meaningful incentives and protection, innovation will remain rare rather than becoming a widespread industry objective.

India has already proven its strength in reverse engineering and generic drug manufacturing, a success that helped establish its global pharmaceutical reputation. The next phase of growth should focus on innovation-driven development—discovering new molecules, advancing biologics and cutting-edge therapies, and creating medicines that originate in Indian laboratories before reaching patients around the world. The country’s ambition should extend beyond being a manufacturing powerhouse. India now has the opportunity to become a global center for pharmaceutical invention, recognized not only for producing medicines but also for creating them.
Disclaimer: This image is taken from ANI.

Union Commerce and Industry Minister Piyush Goyal on Saturday unveiled the "UK-India CETA Business Utilisation Manual – A Practical Activation Guide for Indian and UK Businesses" in London, ahead of the implementation of the India-UK Comprehensive Economic and Trade Agreement (CETA), which is set to take effect on July 15.

Prepared jointly by the UK India Business Council (UKIBC) and HSBC India, the manual is intended to help businesses understand and take advantage of the opportunities created by the landmark trade agreement. The guide breaks down the provisions of the deal into practical, sector-specific recommendations, offering companies a roadmap for maximizing its benefits. The launch took place at a business event organized by FICCI with support from UKIBC, bringing together senior corporate leaders from India and the United Kingdom at a significant juncture in bilateral economic relations.

According to a statement released on the occasion, leaders from both nations have consistently emphasized the importance of strengthening cooperation in areas such as trade, innovation, and advanced technologies. The statement also highlighted a series of recent high-level interactions, including discussions involving Prime Minister Narendra Modi, UK Prime Minister Keir Starmer’s visit to India in 2025, earlier engagements by Deputy Prime Minister David Lammy, and a recent visit by UK Secretary of State for Business and Trade Peter Kyle.

Trade ties between the two countries have continued to expand, with bilateral commerce reaching approximately £47.9 billion (around USD 56–60 billion) in the four quarters ending in Q4 2025. This represents a 10 percent increase compared to previous years and reflects the growing strength of the India-UK economic partnership.

Speaking at the launch, HSBC India CEO Hitendra Dave said the bank’s strong presence in both markets and expertise in international banking and trade finance would help businesses navigate evolving cross-border opportunities. He noted that the CETA framework is expected to improve market access, increase certainty for businesses, and encourage deeper commercial collaboration.

UKIBC Group CEO Kishore Jayaraman described the agreement as a milestone in one of the world’s most important economic relationships. He said the newly launched manual serves as a practical guide that translates the complexities of the trade pact into actionable steps for businesses operating in both countries. He added that UKIBC remains committed to helping companies fully understand and benefit from the agreement. UKIBC, a not-for-profit organization focused on policy advocacy and strategic consulting, works to promote trade and investment between the UK and India by assisting businesses and universities seeking opportunities in both markets.
Disclaimer: This image is taken from ANI.

The Reserve Bank of India (RBI) has released the final guidelines aimed at expanding the country’s credit derivatives market, allowing broader participation and greater use of instruments such as Credit Default Swaps (CDS) and total return swaps. The central bank announced the move on Thursday, with the new framework coming into effect immediately from June 25, 2026. The development follows the government’s proposal in the Union Budget 2026 to strengthen India’s credit derivatives ecosystem and provide market participants with better tools for managing credit risks.

Under the new rules, resident non-retail users will be permitted to use credit derivative instruments, including CDS and total return swaps, without restrictions on their purpose. However, non-resident participants will be allowed to use these instruments mainly for hedging activities. For resident retail users, excluding individuals, CDS transactions will be permitted only for risk protection purposes. The RBI clarified that such users can purchase credit protection only to hedge their existing exposure.

The updated framework also allows credit derivative contracts involving non-residents to be settled either in Indian rupees or foreign currency, depending on the terms of the agreement. The RBI has expanded the list of eligible participants who can act as protection sellers. Insurance companies, pension funds, mutual funds, Alternative Investment Funds (AIFs), and Foreign Portfolio Investors (FPIs) will now be allowed to sell credit protection under the revised guidelines.

The central bank said it reviewed the draft directions after receiving feedback from stakeholders and incorporated necessary changes into the final Master Directions. Regarding exchange-traded credit derivatives, the RBI stated that stock exchanges will be allowed to introduce standardised single-name CDS contracts and credit index-based CDS products with guaranteed settlement mechanisms. However, exchanges will need prior approval from the RBI before launching any such product, including approval for contract design, eligible participants, and other related features.

The new rules also permit FPIs to participate in credit index futures trading, but with certain safeguards to prevent excessive speculation. FPIs will not be allowed to build large short positions or trade credit index futures linked to very short-term debt instruments. The RBI’s move is expected to improve risk management options for financial institutions, increase market depth, and support the development of a more advanced credit derivatives market in India.
Disclaimer: This image is taken from ANI.

On the 2 July episode of Open For Business, Andrea Heng and Hairianto Diman sit down with Lorraine Tan, Morningstar's Director of Equity Research for Asia, for an in-depth analysis of the markets.

Disclaimer: This podcast is taken from CNA.

In a world increasingly dominated by digital wallets and quick online payments, cash is often viewed as outdated. Yet, for many people — from elderly citizens concerned about digital scams to families making everyday purchases at hawker centres — physical money remains a dependable and familiar way to pay. Andrea Heng and Hairianto Diman explore the importance of creating a payment ecosystem that remains accessible and inclusive for all. They speak with Wong Wanyi, FinTech Leader at PwC Singapore, about the role of cash in a rapidly changing financial landscape.

Disclaimer: This podcast is taken from CNA.

A decade after the Brexit referendum, the United Kingdom is again facing a leadership transition, with the departure of Prime Minister Keir Starmer set to bring the country its seventh prime minister in just over 10 years. This frequent turnover reflects the ongoing political instability linked to the long-term effects of the Brexit. As nominations open on 9 July and a new prime minister is expected by September, analysts are examining what this latest leadership crisis reveals about Brexit’s lasting impact on British politics and governance, including insights from political analyst Alexander Hilton of Skystamper.
Disclaimer: This podcast is taken from CNA.

Elon Musk has reportedly become the world’s first trillionaire, driven largely by SpaceX, whose massive IPO has pushed its valuation above $2 trillion. At the same time, huge investments in artificial intelligence are lifting other major tech companies like OpenAI and Anthropic, both of which are expected to go public with valuations nearing a trillion dollars. According to The Guardian’s US tech editor Blake Montgomery in conversation with Kai Wright, these IPOs mean that the global financial system is becoming increasingly tied to the success of AI—and potentially exposed to significant risk if it fails.

Disclaimer: This podcast is taken from The Guardian.